ST PharmLtd Toekomstige groei

Future criteriumcontroles 5/6

ST PharmLtd zal naar verwachting groeien in winst en omzet met respectievelijk 40.2% en 20.3% per jaar. De winst per aandeel zal naar verwachting groeien met 39% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 13.1% zijn.

Belangrijke informatie

40.2%

Groei van de winst

39.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	37.9%
Inkomstengroei	20.3%
Toekomstig rendement op eigen vermogen	13.1%
Dekking van analisten	Good
Laatst bijgewerkt	04 Nov 2024

Recente toekomstige groei-updates

Recent updates

ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Shares Climb 29% But Its Business Is Yet to Catch Up

Aug 30

ST Pharm Co.,Ltd. (KOSDAQ:237690) Stock Rockets 54% As Investors Are Less Pessimistic Than Expected

Mar 18

Investors Who Bought ST PharmLtd (KOSDAQ:237690) Shares A Year Ago Are Now Up 221%

Mar 16

Calculating The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)

Jan 22

What Type Of Shareholders Own The Most Number of ST Pharm Co.,Ltd. (KOSDAQ:237690) Shares?

Dec 23

Health Check: How Prudently Does ST PharmLtd (KOSDAQ:237690) Use Debt?

Nov 26

Winst- en omzetgroeiprognoses

KOSDAQ:A237690 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (KRW Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	460,508	71,000	38,514	61,589	10
12/31/2025	371,118	53,500	18,029	52,689	10
12/31/2024	294,282	40,360	-9,329	42,886	7
6/30/2024	272,887	21,706	-23,243	22,468	N/A
3/31/2024	286,069	22,027	-31,825	8,854	N/A
12/31/2023	284,992	19,581	-42,145	1,298	N/A
9/30/2023	264,760	11,544	-46,308	7,917	N/A
6/30/2023	269,638	17,810	-37,321	24,400	N/A
3/31/2023	262,987	19,882	-36,394	31,641	N/A
12/31/2022	249,322	18,000	-53,339	7,031	N/A
9/30/2022	200,659	10,981	-57,575	1,971	N/A
6/30/2022	186,130	8,285	-50,022	6,557	N/A
3/31/2022	175,363	10,241	-37,812	14,203	N/A
12/31/2021	165,642	3,312	-44,648	7,270	N/A
9/30/2021	161,689	3,841	-43,776	489	N/A
6/30/2021	137,778	-10,640	-35,930	-4	N/A
3/31/2021	131,198	-13,064	-46,419	-23,126	N/A
12/31/2020	124,109	-12,147	-38,379	-20,935	N/A
9/30/2020	115,724	-17,794	-35,929	-28,123	N/A
6/30/2020	113,385	-11,788	-39,485	-31,636	N/A
3/31/2020	97,736	-17,366	-27,574	-20,374	N/A
12/31/2019	93,257	-18,529	-36,608	-30,517	N/A
9/30/2019	74,084	-17,228	-32,516	-25,384	N/A
6/30/2019	67,420	-22,920	-37,753	-22,816	N/A
3/31/2019	85,107	-15,330	-34,743	-17,456	N/A
12/31/2018	97,738	-9,268	-16,545	10,767	N/A
9/30/2018	132,399	6,823	-13,732	21,795	N/A
6/30/2018	162,380	21,376	3,610	37,041	N/A
3/31/2018	183,300	32,346	N/A	44,234	N/A
12/31/2017	202,800	44,997	N/A	54,437	N/A
9/30/2017	193,639	48,990	N/A	55,544	N/A
6/30/2017	204,253	57,391	N/A	63,059	N/A
3/31/2017	217,291	65,196	N/A	78,773	N/A
12/31/2016	200,362	61,426	N/A	50,778	N/A
9/30/2016	198,740	58,742	N/A	75,467	N/A
6/30/2016	190,495	54,579	N/A	65,683	N/A
12/31/2015	138,052	25,189	N/A	35,822	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei A237690 ( 40.2% per jaar) ligt boven de spaarquote ( 2.7% ).

Winst versus markt: De winst van A237690 ( 40.2% per jaar) zal naar verwachting sneller groeien dan de KR markt ( 29.2% per jaar).

Hoge groeiwinsten: De winst van A237690 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van A237690 ( 20.3% per jaar) zal naar verwachting sneller groeien dan de markt KR ( 9.9% per jaar).

Hoge groei-inkomsten: De omzet van A237690 ( 20.3% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen A237690 zal naar verwachting over 3 jaar laag zijn ( 13.1 %).

ST PharmLtd Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 14%

Consensus EPS estimates increase by 17%

Consensus EPS estimates increase by 11%

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 11%

Price target decreased to ₩127,000

Recent updates

Consensus EPS estimates fall by 14%

ST Pharm Co.,Ltd.'s (KOSDAQ:237690) Shares Climb 29% But Its Business Is Yet to Catch Up

Consensus EPS estimates increase by 17%

Is Now The Time To Put ST PharmLtd (KOSDAQ:237690) On Your Watchlist?

Investor sentiment deteriorates as stock falls 20%

ST Pharm Co.,Ltd. to Report Q2, 2024 Results on Jul 25, 2024

New major risk - Share price stability

Is ST Pharm Co.,Ltd. (KOSDAQ:237690) Trading At A 41% Discount?

Now 23% undervalued

ST Pharm Co.,Ltd. to Report Q1, 2024 Results on May 02, 2024

Why ST PharmLtd's (KOSDAQ:237690) Earnings Are Better Than They Seem

Full year 2023 earnings: EPS misses analyst expectations

ST Pharm Co.,Ltd. (KOSDAQ:237690) Stock Rockets 54% As Investors Are Less Pessimistic Than Expected

ST Pharm Co.,Ltd., Annual General Meeting, Mar 25, 2024

ST Pharm Co.,Ltd., Annual General Meeting, Mar 25, 2024

Now 21% undervalued

Consensus EPS estimates increase by 11%

ST Pharm Co.,Ltd. to Report Fiscal Year 2023 Results on Feb 01, 2024

Upcoming dividend of ₩500 per share at 0.8% yield

Consensus EPS estimates fall by 12%

ST Pharm Co.,Ltd. announced that it has received KRW 100 billion in funding

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates increase by 11%

Upcoming dividend of ₩500 per share

Price target decreased to ₩127,000

Less than half of directors are independent

Now 21% undervalued after recent price drop

Consensus forecasts updated

Consensus forecasts updated

Price target increased to ₩155,000

Less than half of directors are independent

Full year 2020 earnings released: ₩651 loss per share (vs ₩993 loss in FY 2019)

Investors Who Bought ST PharmLtd (KOSDAQ:237690) Shares A Year Ago Are Now Up 221%

New 90-day low: ₩73,900

ST Pharm Co.,Ltd., Annual General Meeting, Mar 23, 2021

Calculating The Fair Value Of ST Pharm Co.,Ltd. (KOSDAQ:237690)

ST Pharm Co.,Ltd. to Report Q4, 2020 Results on Jan 25, 2021

What Type Of Shareholders Own The Most Number of ST Pharm Co.,Ltd. (KOSDAQ:237690) Shares?

ST Pharm Co.,Ltd. announced that it has received KRW 110 billion in funding

Health Check: How Prudently Does ST PharmLtd (KOSDAQ:237690) Use Debt?

New 90-day high: ₩74,600

New 90-day high - ₩65,700

New 90-day high - ₩53,000

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven